About JHL

Who We Are

JHL Biotech is a globally-focused biopharmaceutical company that develops own biosimilars and accelerate the development programs of select partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biosimilar products, from cell line development to commercial manufacturing.

Developing Proprietary Biosimilar Pipeline

We are developing proprietary biosimilar pipeline through process innovation, unwavering commitment to quality and its own manufacturing infrastructure.

Collaboration & Licensing of Innovative Biologics

We licence-in innovative new molecules for co-development that we believe offer benefits over current standards of care.

Contract Manufacturing Partnerships

We provide high quality, reasonable priced Contract Development and Manufacturing Services (CDMO) to accelerate the development programs of select partners.

History

Founded in 2012, JHL is an innovator in biopharmaceuticals that utilizes breakthrough engineering and process technologies to provide high quality and affordable biosimilar medicines to patients in need.

Development Highlights

August 2017 Enrolled 38 randomized patients in ongoing EU trial of JHL1101
April 2017 CTA for use of JHL1101 in Phase 1 and Phase 3 clinical trials in Non-Hodgkin’s Lymphoma patients has been accepted by for review
December 2016 Announced strategic biologics alliance with Sanofi
February 2016 Announced mechanical completion of its Wuhan Biopharmaceutical manufacturing facility

JHL1101 EU clinical trial approval

September 2015 Publicly listed on the Taiwan Emerging Market StockExchange
June 2014 Closed US$35 million Series B financing

JHL is strong and flexible like the stalks of the bamboo.  The strength comes from everyone’s expertise and ability to work together to meet the common goal of making world-class biopharmaceuticals affordable and accessible to all patients globally.  The flexibility comes from being able to adjust to situations to resolve challenges that we may face.